ARCHIVES

A Take-Home Message From ASCO 2014: NCI-Funded Clinical Research In Jeopardy,bSociety Focuses on Value of NCTN Groups

This article is from The Cancer Letter archive.

Vol. 40 No. 23 | June 6, 2014

Download PDF Visit The Full Archive

Related Articles

BRAF Inhibitor Shrank Tumors In Phase II Genentech Study

November 26, 2010

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

November 7, 2003

Clinton to Propose Increase for NIH & NCI Significantly Higher Than In Previous Years

January 9, 1998

FDA Should Delay Provenge Decision Pending Definitive Trial Results, ODAC Chairman Writes.

April 27, 2007

Facing Congressional Criticism, NIH Starts Review of Extramural Conflict Policies.

June 13, 2008

In Brief: Jane Henney Sworn In As FDA Commissioner; Six Centers Retain Comprehensive Status

December 18, 1998